Clinical Trial Update: BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of BL22 immunotoxin in patients with refractory chronic lymphocytic leukemia, prolymphocytic leukemia, and non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma
• Prolymphocytic Leukemia

Drugs mentioned

• BL22 Immunotoxin (BL22 immunotoxin)

Snippet

Sponsor: MedImmune LLC | Conditions: Leukemia, Lymphoma | Phase 1 | Status: COMPLETED